Eptifibatide: uses, dosing, side effects & brands

Eptifibatide is a platelet aggregation inhibitor sold in the U.S. under 2 brand and generic names, for unstable angina, coronary disease and myocardial infarction. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.

By the pharmaranks editorial teamReviewed against the FDA (openFDA label, NDC Directory & Enforcement) sourcesUpdated Jul 24, 2026How we research

Key facts

Drug class: Platelet Aggregation Inhibitor
Treats (across its forms): Unstable Angina, Coronary Disease and Myocardial Infarction
Available as: Injectable · Solution
Sold as: 2 products — Eptifibatide and Integrilin
Prescription?: Prescription only
Generic available?: Yes

How eptifibatide is dosed

From the FDA label for Eptifibatide (application ANDA203258). Other eptifibatide products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.

Before infusion of eptifibatide injection, the following laboratory tests should be performed to identify pre-existing hemostatic abnormalities: hematocrit or hemoglobin, platelet count, serum creatinine, and PT/aPTT. In patients undergoing PCI, the activated clotting time (ACT) should also be measured. The activated partial thromboplastin time (aPTT) should be maintained between 50 and 70 seconds unless PCI is to be performed. In patients treated with heparin, bleeding can be minimized by close monitoring of the aPTT and ACT. ACS or PCI: 180 mcg/kg IV bolus as soon as possible after diagnosis followed by infusion at 2 mcg/kg/min. ( 2.1 , 2.2 ) PCI: Add a second 180 mcg/kg bolus at 10 minutes. ( 2.2 ) In patients with creatinine clearance less than 50 mL/min, reduce the infusion to 1 mcg/kg/min. ( 2.1 , 2.2 , 2.3 ) 2.1 Dosage in Acute Coronary Syndrome (ACS) Indication Normal Renal Function Creatinine Clearance less than 50 mL/min Patients with ACS 180 mcg/kg intravenous (IV) bolus as soon as possible after diagnosis, followed by continuous infusion of 2 mcg/kg/min 180 mcg/kg IV bolus as soon as possible after diagnosis, followed by continuous infusion of 1 mcg/kg/min • Infusion should continue until hospital discharge or initiation of coronary artery bypass graft surgery (CABG), up to 72 hours • If a patient is to undergo PCI, the infusion should be continued until hospital…

Eptifibatide side effects

The following serious adverse reaction is also discussed elsewhere in the labeling: • Bleeding [see Contraindications (4) and Warnings and Precautions (5.1) ] Bleeding and hypotension are the most commonly reported adverse reactions. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Mylan at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. A total of 16,782 patients were treated in the Phase III clinical trials (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Eptifibatide Therapy (PURSUET), Enhanced Suppression of the Platelet IIb/IIIa Receptor with Eptifibatide Therapy (ESPRET), and Eptifibatide to Minimize Platelet Aggregation and Prevent Coronary Thrombosis II (EMPACT II)) [see Clinical Studies (14)] . These 16,782 patients had a mean age of 62 years (range: 20 to 94 years). Eighty-nine percent of the patients were Caucasian, with the remainder being predominantly Black (5%) and Hispanic (5%). Sixty-eight percent were men. Because of the different regimens used in PURSUET, EMPACT II, and ESPRET, data from…

Who shouldn’t take eptifibatide

Treatment with eptifibatide is contraindicated in patients with: • A history of bleeding diathesis, or evidence of active abnormal bleeding within the previous 30 days • Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy • Major surgery within the preceding 6 weeks • History of stroke within 30 days or any history of hemorrhagic stroke • Current or planned administration of another parenteral GP IIb/IIIa inhibitor • Dependency on renal dialysis • Hypersensitivity to eptifibatide or any component of the product (hypersensitivity reactions that occurred included anaphylaxis and urticaria) • Bleeding diathesis or bleeding within the previous 30 days ( 4 ) • Severe uncontrolled hypertension ( 4 ) • Major surgery within the preceding 6 weeks ( 4 ) • Stroke within 30 days or any history of hemorrhagic stroke ( 4 ) • Coadministration of another parenteral GP IIb/IIIa inhibitor ( 4 ) • Dependency on renal dialysis ( 4 ) • Known hypersensitivity to any component of the product ( 4 )

Eptifibatide drug interactions

Coadministration of antiplatelet agents, thrombolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. Avoid concomitant use with other glycoprotein (GP) IIb/IIIa inhibitors. ( 7.1 ) 7.1 Use of Thrombolytics, Anticoagulants, and Other Antiplatelet Agents Coadministration of antiplatelet agents, thrombolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. Concomitant treatment with other inhibitors of platelet receptor GP IIb/IIIa should be avoided.

Every eptifibatide product we track (2)

Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.

Eptifibatide products
#	Drug	Rating	Type	Form	Generic?	Pharmacy pays
1	Eptifibatide	66/100	Prescription	Injectable	No data	—	View →
2	Integrilin	Not yet rated	Prescription	Injectable	No data	—	View →

Eptifibatide recalls

From the FDA Enforcement database. A recall covers specific lots — not the drug as a whole.

How long eptifibatide keeps

The date on a sealed pack is not the only one: some eptifibatide labels start a second clock once the product is opened or mixed, as short as 2 months.

Does eptifibatide expire? The in-use limits and storage rules from its labels

What people report to the FDA about eptifibatide

The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 893 reports naming eptifibatide, and the FDA flagged 73% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:

myocardial infarction215 reports
thrombocytopenia93 reports
hypotension46 reports
haemoglobin decreased45 reports
haemorrhage41 reports
acute myocardial infarction37 reports
thrombosis in device32 reports
haematoma28 reports

Read these as a signal, not a rate. A report does not mean eptifibatide caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.

Source: openFDA drug/event (FAERS), retrieved July 25, 2026.

Related calculators

How long it stays in your system →

Frequently asked questions

What is eptifibatide?

Eptifibatide is a cyclic heptapeptide containing 6 amino acids and 1 mercaptopropionyl (des-amino cysteinyl) residue. An interchain disulfide bridge is formed between the cysteine amide and the mercaptopropionyl moieties.

What kind of drug is eptifibatide?

The FDA classifies eptifibatide as a platelet aggregation inhibitor. If you are checking whether it is safe to combine with something else, the class is what matters — two drugs from the same class usually should not be stacked.

Can you take eptifibatide with other medicines?

It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run eptifibatide against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.

What brand names is eptifibatide sold under?

We track 2 eptifibatide-containing products in the U.S.: Eptifibatide and Integrilin. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.

What forms does eptifibatide come in?

Across the brands we track, eptifibatide is currently marketed as injectable and solution, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.

Is there a generic eptifibatide?

Yes. Our catalog lists 1 generic eptifibatide product alongside the brand versions. A generic has the same active ingredient and must meet the FDA's bioequivalence standard; it usually costs less. Ask your pharmacist which one your plan covers.

Has eptifibatide been recalled?

The FDA's Enforcement database lists 2 recall records whose product description mentions eptifibatide. The most recent: Eptifibatide Injection (Feb 12, 2026). A recall applies to specific lots, not to the drug as a whole — check the record for the affected lot numbers.

Cite this page

APA: pharmaranks. (2026, July 24). Eptifibatide: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/eptifibatide
MLA: “Eptifibatide: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/eptifibatide.

We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.

Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.

Read the full FDA label for eptifibatide on DailyMed (NIH) ↗.